Go offline with the Player FM app!
Ozempic Made Novo Nordisk a Giant. Here's Why It's Stock Might Be Undervalued
Manage episode 489639953 series 3439723
Ozempic’s still the hottest drug on the planet.
But Novo Nordisk’s stock? Not so much. It’s down nearly 50% from its peak, and investors aren’t sure whether to double down or walk away.
In today’s episode, Finimize Analyst Russell Burns, whose latest research unpack's what’s really going on with the stock, joins the pod.
Is this just a healthy correction? Or the kind of long-term opportunity you only get when everyone else is panicking?
132 episodes
Manage episode 489639953 series 3439723
Ozempic’s still the hottest drug on the planet.
But Novo Nordisk’s stock? Not so much. It’s down nearly 50% from its peak, and investors aren’t sure whether to double down or walk away.
In today’s episode, Finimize Analyst Russell Burns, whose latest research unpack's what’s really going on with the stock, joins the pod.
Is this just a healthy correction? Or the kind of long-term opportunity you only get when everyone else is panicking?
132 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.